| pubmed-article:3073076 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C0011881 | lld:lifeskim |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C0006938 | lld:lifeskim |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C0028066 | lld:lifeskim |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3073076 | lifeskim:mentions | umls-concept:C0232105 | lld:lifeskim |
| pubmed-article:3073076 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:3073076 | pubmed:dateCreated | 1989-6-14 | lld:pubmed |
| pubmed-article:3073076 | pubmed:abstractText | In these studies, the effect of a 6-wk treatment by placebo, the calcium-channel blocker nifedipine, or the converting-enzyme inhibitor captopril was assessed in normotensive patients with insulin-dependent diabetes and incipient nephropathy. In response to captopril and nifedipine, arterial pressure decreased slightly and to a similar extent. These drugs resulted in opposite effects on urinary excretion of albumin [i.e., increase in urinary albumin excretion (UAE) by 40% during nifedipine treatment and decrease by 40% during captopril treatment]. No change in UAE was observed in the placebo group. This observation of opposite changes in UAE in the presence of a similar fall in arterial pressure suggests that the effects of captopril and nifedipine on UAE result from some difference in their intrarenal action. The data do not present recommendations for the use or disuse of captopril or nifedipine in such a group of patients and do not allow extrapolation to hypertensive diabetic subjects well controlled by other conventional antihypertensive agents. | lld:pubmed |
| pubmed-article:3073076 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3073076 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3073076 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3073076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3073076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3073076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3073076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3073076 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3073076 | pubmed:issn | 0149-5992 | lld:pubmed |
| pubmed-article:3073076 | pubmed:author | pubmed-author:MonnierLL | lld:pubmed |
| pubmed-article:3073076 | pubmed:author | pubmed-author:MimranAA | lld:pubmed |
| pubmed-article:3073076 | pubmed:author | pubmed-author:BringerJJ | lld:pubmed |
| pubmed-article:3073076 | pubmed:author | pubmed-author:RibsteinJJ | lld:pubmed |
| pubmed-article:3073076 | pubmed:author | pubmed-author:InsuaAA | lld:pubmed |
| pubmed-article:3073076 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3073076 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:3073076 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3073076 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3073076 | pubmed:pagination | 850-3 | lld:pubmed |
| pubmed-article:3073076 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:meshHeading | pubmed-meshheading:3073076-... | lld:pubmed |
| pubmed-article:3073076 | pubmed:articleTitle | Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. | lld:pubmed |
| pubmed-article:3073076 | pubmed:affiliation | Department of Medicine, Centre Hospitalier Universitaire, Montpellier, France. | lld:pubmed |
| pubmed-article:3073076 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3073076 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3073076 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3073076 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3073076 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3073076 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3073076 | lld:pubmed |
